{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-029210","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.677590+00:00","generated_at":"2026-05-15T00:20:02.672090+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Arvinas gets FDA approval for VEPPANU (vepdegestrant) in ESR1m breast cancer; first PROTAC approved","bullets":["FDA approved VEPPANU for ER+/HER2-, ESR1-mutated advanced/metastatic breast cancer after at least one prior endocrine therapy.","VEPPANU is the first FDA-approved PROTAC degrader; approval came before June 5, 2026 PDUFA date.","Arvinas to receive $50M development milestone payment from collaborator Pfizer upon approval.","Arvinas and Pfizer on track to select third-party for VEPPANU commercialization.","Phase 3 VERITAC-2: vepdegestrant reduced risk of progression or death by 43% vs fulvestrant (HR 0.57, p=0.0001)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-029210","json":"https://secwatch.observer/filing/0001628280-26-029210.json","markdown":"https://secwatch.observer/filing/0001628280-26-029210.md","text":"https://secwatch.observer/filing/0001628280-26-029210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026029210/0001628280-26-029210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026029210/arvn-20260501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:20:02.672090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}